GLP-2 20mg

▎ GLP-2 Struktrɔ

▎ GLP-2 Risach

Wetin na di risach bakgrɔn fɔ GLP-2?

di risεch bakgrכn fכ GLP-2 fכs kכmכt frכm di εksplכreshכn fכ mεtabolism tritmεnt drog dεm εn di dimand fכ weit mεnejmεnt drog dεm. Tradishonal mεtabolism tritmεnt drog dεm gεt limitεshכn, we GLP-1 rεsεptכr agonist dεm de sho sכm εfεktiv fכ impruv bכdi glukכs kכntrכl, we de mek risechכr dεm fכ divεlכp mכr ifektiv drog dεm fכ di sem klas. as GIP/GLP-1 dual risεptor agonist, GLP-2 kin bεtε rεgεl di blכd glukכs lεvεl. Di glob ɔl inkris pan ɔvaweit ɛn fat pipul dɛm dɔn mek weit kɔntrol na wan klinik nid kwik kwik wan. GLP-1 rεsεptכr agonist dεm gεt weit-rεdyusin ifekt dεm, we de mek dεn bi tכgεt fכ weit lכs. GLP-2 dɔn gɛt atɛnshɔn bikɔs ɔf in fayn fayn wet-lɔs autkam dɛn.

Wetin na di mεkanism fכ akshכn fכ GLP-2?

Dual rεsεptכr agonist akshכn: 

GLP-2 na dual glukagon-layk pεptida-1 (GLP-1) εn glukכs-dipεndεnt insulinotropik polipεptida (GIP) rεsεptכr agonist [1,2](Wong E, 2023; Kumar D, 2022). GLP-1 εn GIP na dεn tu inkrεtin כmon dεm we dεn prodyuz insay di intestin, we de ple imכtant rol fכ mεnten glukכs homכstasis. GLP-2 de sho wan sinagεstik ifekt bay we i de aktibכt di GLP-1 εn GIP rεsεpכta dεm wan tεm, we de mek i de rεgεl di blכd glukכs lεvεl.

Rεgulεshכn fכ insulin εn glukagon sekreshכn: 

i de inkrεs insulin sεntesis εn sekreshכn we i de ridyus glukכn rilis insay wan we we dipεnd pan glukכs. we di blכd glukכs lεvεl go כp, GLP-2 de mek di pankrεas β-sεl dεm fכ sekret insulin, we de mek di glukכs tek εn yutilizeshכn, we de mek di blכd glukכs lεvεl dכn; di sem tεm, i de inhεbit di pankrias α-sεl dεm fכ sekret glukagon, i de ridyus di hεpatik glukכs autput, fכ lכs di blכd glukכs lεvεl, εn i de kכntrכl di fasting εn postprandial bכdi glukכs lεvεl dεm fayn fayn wan ^[1,3]..

Ɔda we dɛn fɔ du sɔntin: 

GLP-2 de promuot bak satiety, we kin riliyt to aktibכt GLP-1 rεsεpכta dεm, akt pan di sεntri nεv sεstem, εn infכlכw apetit rεguleshכn sεnta dεm, we de mek di sikman dεm ridyus di it we dεn de it εn dat de εp fכ lכs di wet. i de mek bak di gεstrik εmpti, i de mek di tεm we di it de insay di bεlε lכng εn i de go insay di sכmכl intestin sכmtεm, we de mek di glukכs lεvεl na di bכdi nכ go כp kwik kwik wan ^[1]..

Figure 1 Mεkanism fכ akshכn fכ T irzepatide ^[6]..

Wetin na di aplikeshɔn dɛn fɔ T irzepatide?

Tritmɛnt fɔ tayp 2 mɛtabolism: 

GLP-2 na aprɔv fɔ trit big pipul dɛn we gɛt tayp 2 mɛtabolism as adjɔnt to it ɛn ɛksɛsayz. di SURPASS trayal sho se GLP-2 de ridyus di hεmoglobin A1c (HbA1c) lεvεl dεm sכmtεm, wit rεdukshכn we de frכm -1.87% to -2.59% (-20 to -28 mmol/mol). i de sho bak supεriכr glycemic kכntrכl kכmpεr to sכm GLP-1 rεsεptכr agonist dεm, lεk GLP-1 1 mg insay di SUPRASS-2 trayal. apat frכm dat, i kin ridyus di bכdi wet, wit weit lכs we de frכm -6.2 to -12.9 kg insay klinik stכdi dεm, we na patikyuכl sכmtin fכ di sik pipul dεm we gεt tayp 2 mεtabolism we kin gεt כva wet כ fכ fat εshyu ^[1,4]..

Di tritmɛnt fɔ di wan dɛn we fat: 

Bikɔs GLP-2 de mek pɔsin satisfay, i de mek i nɔ it bɔku tin, ɛn i de mek i nɔ gɛt bɔku bɔku bɔdi, i gɛt pɔtnɛshɛl tritmɛnt valyu fɔ di wan dɛn we fat. Stɔdi dɔn sho se i kin ridyus di wet pas 20%, i kin mek di sikman dɛn mɛtabolik stej bɛtɛ, ɛn i kin bi nyu tritmɛnt opshɔn fɔ fat, i kin ɛp di wan dɛn we fat fɔ lɔs dɛn wet ɛn ridyus di risk fɔ gɛt difrɛn sik dɛn we gɛt fɔ du wit fat ^[1,2]..

Ridyus risk fɔ gɛt sik dɛn we de ambɔg di at ɛn di blɔd: 

Bɔrku tɛm, di wan dɛm wae gɛt tayp 2 mɛtabolism kin gɛt bɔrku risk fɔ gɛt sik na dɛn at ɛn blɔd. Apat frɔm we i de stɔp di blɔd shuga ɛn wet, GLP-2 gɛt fayn ifɛkt pan di indikɛtɔ dɛn we gɛt fɔ du wit di at ɛn di blɔd, lɛk fɔ ridyus blɔd prɛshɔn, fɔ ridyus di visɛral fat we de gɛda, ɛn fɔ mek di triglisrayd lɛvɛl we de na di blɔd go dɔŋ, ɛn dis de ɛp fɔ ridyus di risk fɔ gɛt di sik we de ambɔg di at ɛn di blɔd ɛn fɔ mek di sikman dɛn at ɛn blɔd autkam fayn ^[4]..

Pɔtɛnɛshɛl tritmɛnt fɔ nɔ-alkohol stiatohepatitis (NASH): 

GLP-2 gɛt pɔtɛnɛshɛl tɛrapi ifɛkt pan NASH. bay we i de impruv insulin sεnsitiviti εn rεgεl glukכs εn lipid mεtabolism, i kin ridyus hεpatik stεatosis εn inflameshn, we de gi nyu dairekshכn fכ NASH tritmεnt ^[5]..

Dɔn

as GIP/GLP-1 dual rεsεptכr agonist, GLP-2 dεn dכn sho sכm sכm efεktiv in di tritmεnt fכ mεtabolism εn mεtabolik dizכrd dεm. bay we i de rεgεl insulin εn glukagon sekreshכn, delay di gεstrik εmpti, εn εnhans satie, i de bכku bכku wan lכs di hεmoglobin A1c lεvεl εn ridyus di sikman in wet. Apat frɔm dat, di drɔg de ɛp fɔ mek di tin dɛn we kin mek pɔsin gɛt prɔblɛm wit di at ɛn di blɔd blɔd lɛk di lipid lɛvɛl ɛn di blɔd prɛshɔn ɛn i kin sho se i wok fayn pan stiatohepatitis we nɔ gɛt alkol.

Bɔt di pɔsin we rayt di buk

Di tin dɛn we wi dɔn tɔk bɔt, na ɔl di tin dɛn we Cocer Peptides dɔn du risach, ɛdit ɛn kɔmpilayt.

Sayɛns Jɔnal Author

De Block C gɛt fɔ du wit di Yunivasiti ɔf Antwɛp ɛn di institiushɔn dɛn we gɛt fɔ du wit am na Bɛljiɔm, we inklud di Inflamed Ctr Ɛksɛlɛns, Yunivasiti Ospital Antwɛp (UZA ɛn Univ Hosp Antwɛp), ɛn di Infla Med Ctr Ɛksɛlɛns. In risach de span sɔm disiplin dɛm, lɛk Endocrinology & Diabetes, usay i de pe atɛnshɔn pan ɔmon ɛn mɛtabolik dizayd; Gastroenterology & Hepatology, we de εksplכr digεstiv εn liva sik dεm; Jɛnɛral & Intanɛt Mɛdisin, we de adrɛs di diagnosis ɛn manejmɛnt fɔ kɔmɔn intanɛnt sik dɛm; Nutrition & Dietetics, we de invɛstigat nyutrishɔn ɛn in wɛlbɔdi impak dɛm; ɛn Urology & Nephrology, we de stɔdi di patɔlɔji ɛn klinik prɔsis fɔ urinary ɛn kidni sik dɛn. I na masta sabi bukman we dɔn ɛp fɔ du bɔku tin dɛn we gɛt fɔ du wit mɛrɛsin. De Block C de list in di rεfrεns כf saytεshכn [4].

▎ Saytayshɔn dɛn we gɛt fɔ du wit dis

[1] Wong E, Kɔp R, Dima L, ɛn ɔda pipul dɛn. GLP-2: Wan Dual Glucose-dipεndεnt Insulinotropic Polypeptide εn Glucagon-Lεk Pεptid-1 Agonist fכ di Mεnejmεnt fכ Tayp 2 Dayabitis Mεlitus[J]. Amɛrikan Jɔnal fɔ Tɛrapi, 2023,30(1):e26-e35.DOI:10.1097/MJT.0000000000001588.

[2] Kumar D, Harshidha D, Mousigan M, ɛn ɔda pipul dɛn. Wan Ovaviu pan GLP-2, Dual-Targeted Tritmɛnt fɔ Dayabitis ɛn Ɔbisiti[J]. Int ɛ rnash ɔ nal J ɔ rnal ɔ f Inovativ Risach & Grɔwth, 2022,7:983.DOI:10.5281/zenodo.7420605.

[3] Sweta, Gupta S, Bansal S, ɛn ɔda pipul dɛn. GLP-2 wan nכvel anti dayabεtik mכlekyul unfold dual akshכn[J]. Diskɔva Pɔblik Ɛlth, 2024,21(1):75.DOI:10.1186/s12982-024-00200-2.

[4] De Blɔk C, Bɛli C, Wysham C, ɛn ɔda pipul dɛn. GLP-2 fכ di tritmεnt fכ big pipul dεm wit tayp 2 mεtabolism: Wan εndokrin pεrspεktiv[J]. Dayabitis Ɔbisiti & Dayabitis, 2023,25 (1): 3-17.DOI: 10.1111/dom.14831.

[5] Sood A, Kaur P, Syed O, ɛn ɔda pipul dɛn. rivכlyushכn mεtabolism kεri: fכ sho di GLP-2 in pכtεnshal in glycemic kכntrכl εn biyכn[J]. Ekspɛkt Rivyu fɔ Klinik Famakɔlɔji, 2024,17(3):235-246.DOI:10.1080/17512433.2024.2310070.

[6] Grovεr-Pεz F, Gכmεz A, Suárez A, εt al. frכm wan glycocentric apכch in di pasεnt wit tayp 2 mεtabolism mεlitus to wan mכlti-כgan prεvεnshכn tritmεnt εn wan dεkrεshכn in di nyuro-nεfrכ-kardiovaskulכr autkam dεm.[M]//2023.DOI: 10.5772/intechopen.1002363.

ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.  

Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto famasitik, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.